ArticleWorld journal of pediatrics : WJP2021
Consensus statement on the epidemiology, diagnosis, prevention, and management of cow's milk protein allergy in the Middle East: a modified Delphi-based study.
Article in World journal of pediatrics : WJP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Cow's Milk Protein Allergy: ETAPA Survey on Pediatric Management and Tolerance Acquisition.Children (Basel, Switzerland) · 2025Article
- Cow milk protein allergy mimics in infancy.World journal of clinical pediatrics · 2025Review
- Clinical, laboratory, and therapeutic differences between immunoglobulin E-mediated and non-immunoglobulin E-mediated cow's milk protein allergy in children.World journal of clinical pediatrics · 2025Article
- Cow's Milk Allergy and Associated Factors Among Children in Abha City, Saudi Arabia - A Retrospective Case Control Study.Journal of asthma and allergy · 2025Article
- Regional differences in diagnosis and management of cow's milk allergy.Clinical and experimental pediatrics · 2024Article
- How consistent are the key recommendations, and what is the quality of guidelines and expert consensus regarding paediatric cow's milk protein allergy?European journal of pediatrics · 2024Article
- Ruptured giant omphalocele with congenital short small intestine: a case report.Frontiers in nutrition · 2024Article
- Symptoms and management of cow's milk allergy: perception and evidence.Frontiers in allergy · 2024Article
- The use of amino acid formulas in pediatric patients with allergy to cow's milk proteins: Recommendations from a group of experts.Frontiers in pediatrics · 2023Review
- Cows' Milk Allergy-Associated Constipation: When to Look for It? A Narrative Review.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to develop an expert consensus regarding the epidemiology, diagnosis, and management of cow's milk protein allergy (CMPA) in the Middle East.
methodsA three-step modified Delphi method was utilized to develop the consensus. Fifteen specialized pediatricians participated in the development of this consensus. Each statement was considered a consensus if it achieved an agreement level of ≥ 80%.
resultsThe experts agreed that the double-blind placebo-controlled oral challenge test (OCT) should be performed for 2-4 weeks using an amino acid formula (AAF) in formula-fed infants or children with suspected CMPA. Formula-fed infants with confirmed CMPA should be offered a therapeutic formula. The panel stated that an extensively hydrolyzed formula (eHF) is indicated in the absence of red flag signs. At the same time, the AAF is offered for infants with red flag signs, such as severe anaphylactic reactions. The panel agreed that infants on an eHF with resolved symptoms within 2-4 weeks should continue the eHF with particular attention to the growth and nutritional status. On the other hand, an AAF should be considered for infants with persistent symptoms; the AAF should be continued if the symptoms resolve within 2-4 weeks, with particular attention to the growth and nutritional status. In cases with no symptomatic improvements after the introduction of an AAF, other measures should be followed. The panel developed a management algorithm, which achieved an agreement level of 90.9%.
conclusionThis consensus document combined the best available evidence and clinical experience to optimize the management of CMPA in the Middle East.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.